Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 14, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
August 08, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
August 07, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
July 30, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
June 25, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
June 24, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s
June 23, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 29, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 20, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
May 13, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
May 08, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
May 07, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
April 30, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
April 02, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
April 01, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
February 20, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Tickers
GUTS
Fractyl Health Announces Pricing of Initial Public Offering
February 01, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform
January 05, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure
December 14, 2023
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting
December 11, 2023
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Expands Landmark Academic-Industry Collaboration to Study Mechanisms Underlying GLP-1-Based Pancreatic Gene Therapy for Type 2 Diabetes and Obesity
November 16, 2023
From
Fractyl Health, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.